British Journal of Nutrition (2020), 123, 1258–1268 © The Authors 2020

doi:10.1017/S000711452000063X

MS British Journal of Nutrition

Urine metabolome alterations in malnutrition and the impact of glycerol or rumen-protected choline chloride supplementation in advanced pregnant ewes

Changzheng Guo^{1,2,3,4,5}, Yanfeng Xue^{1,2,3,4,5}, Yuyang Yin⁶, Haipeng Xuan^{1,2,3,4,5}, Fan Hu^{1,2,3,4} and Shengvong Mao^{1,2,3,4,5,7}*

¹Laboratory of Gastrointestinal Microbiology, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing 210095, People's Republic of China

²Jiangsu Key Laboratory of Gastrointestinal Nutrition and Animal Health, Nanjing Agricultural University, Nanjing 210095, People's Republic of China

³National Experimental Teaching Demonstration Center of Animal Science, Nanjing Agricultural University, Nanjing 210095, People's Republic of China

⁴National Center for International Research on Animal Gut Nutrition, Nanjing Agricultural University, Nanjing 210095, People's Republic of China

⁵Joint International Research Laboratory of Animal Health and Food Safety, Nanjing Agricultural University, Nanjing 210095, People's Republic of China

⁶Huzhou Academy of Agricultural Sciences, Huzhou 313000, People's Republic of China

 7 College of Animal Science and Technology, Shihezi University, Shihezi 832003, People's Republic of China

(Submitted 17 October 2019 - Final revision received 7 February 2020 - Accepted 12 February 2020 - First published online 20 February 2020)

Abstract

The objective of this study was to explore the metabolic profiles of pregnancy malnutrition induced by feed restriction (FR) and the counteracting effects of glycerol and rumen-protected choline chloride supplementation. Two feeding trials were conducted. In the first experiment, twenty pregnant Hu sheep carrying multiple fetuses with a gestation period of 108 d were randomly divided into two groups. The ewes in the control (CON) group were offered 100 % of their nutritional requirements as recommended by the National Research Council (NRC), while the FR group was offered 30 % of feed intake of CON for 15 d. In the second experiment, eighteen pregnant Hu sheep were offered a feed intake comprising 30 % of the NRC-recommended nutritional requirements twice daily. The sheep were randomly divided into three groups: the FR group in the second experiment (FR2), with no supplementation, the glycerol (GLY) group, which received 40 ml of glycerol per d, and the rumen-protected choline chloride (RPC) group, which received 10 g of rumen-protected choline chloride per d for 9 d. In the first experiment, the urine metabolome of sixteen ewes showed significant difference between the CON group and FR group. Compared with the CON group, FR decreased the level of p-glucose, lactic acid, levoglucosan, α -ketoglutarate, phosphohydroxypyruvic acid, glucose 6-phosphate and the methyl donors, while increasing the level of pyruvate, fumaric acid and carnitines in urine. Both the GLY and RPC treatments counteracted some of these changes and modulated the urine metabolome in advanced pregnant ewes suffering from malnutrition.

Key words: Glycerol: Rumen-protected choline chloride: Pregnant ewes: Pregnancy toxemia: Metabolomics

Malnutrition typically occurs in the last third of the gestation period in sheep and goats⁽¹⁾ because of the rapid increase in nutritional demands of the rapidly developing fetal placental unit and the decreased energy intake resulting from reduction in rumen volume^(1,2). In China, the native Hu sheep is more susceptible to malnutrition during pregnancy due to its high fecundity

with a reported average ovulation rate over $2 \cdot 2 - 3 \cdot 14^{(3)}$. Previous studies suggest that malnutrition may result in a concurrent negative energy balance (NEB), which further leads to fat mobilisation stored in adipose tissue to provide energy^(4,5).

However, due to the lack of sufficient oxaloacetate, the acetyl-CoA produced by the oxidation of mobilised fat cannot enter the

Abbreviations: BHBA, β-hydroxybutyric acid; CON, control group; FR, feed restriction; FR2, feed restriction group in the second experiment; GLY, glycerol group; LC, liquid chromatography; MG, monoacylglycerol; NEB, negative energy balance; PA, phosphatidic acid; PCA, principal component analysis; PG, phosphatidylglycerol; PLS-DA, partial least squares-discriminate analysis; RPC, rumen-protected choline chloride group; TCA, tricarboxylic acid.

* Corresponding author: Dr Shengyong Mao, email maoshengyong@njau.edu.cn



tricarboxylic acid (TCA) cycle and instead forms ketone bodies, which could lead to metabolic acidosis, electrolytic spoliation and dehydration, and neurological symptoms⁽¹⁾. In addition, excessive mobilisation of fatty acids accumulates in the liver and causes fatty liver, reducing endogenous glucose production and resulting in a vicious cycle, as the liver is considered to be the primary glucogenic organ^(4,6). To date, the pathogenesis is not completely known due to a lack of understanding of the changes in metabolites and the pathways involved, as well as the effect of treatments for malnutrition⁽¹⁾.

To date, normalising the metabolic parameters was the effective treatment for malnutrition, including providing additional energy sources and improving liver metabolic function. Glucose infusion was the common treatment, while a previous study indicated that glucose infusion could decrease neoglucogenesis, and rapid intravenous injection of glucose led to a transient hyperglycaemia and an increase in urine output⁽⁷⁾. In addition, oral glycerol can directly participate in gluconeogenesis by passage through the rumen⁽⁸⁾ or being fermented in the rumen, producing propionate, the main precursor of glucose, which lead to the increase in blood glucose concentration by a relatively long period⁽⁹⁾, despite the fact that the proportion of ruminal degradation of glycerol and its absorption was inconsistent throughout different studies^(10,11).

However, little research on glycerol treatment for gestational malnutrition in advanced pregnant ewes was conducted, as well as its effect on metabolic profiles. Choline was claimed to be able to improve liver function by increasing VLDL exportation from the liver in transition dairy cows⁽¹²⁾. However, due to various supplementation periods and duration, along with the level of supplementation, the consequences were inconsistent⁽¹²⁾. To the best of our knowledge, there was no research focused on the effect of choline chloride on the metabolic profiles in advanced pregnant ewes suffering from malnutrition.

Metabolomics technology makes it possible to explore global changes in metabolites and the involved metabolic pathways to better understand the disease process. Moreover, it has been used for biomarker identification, disease diagnosis and mechanism exploration in ruminants^(13–15). However, there is dearth of information regarding metabolic processes in advanced pregnant ewes suffering from malnutrition, as well as the effects of glycerol or rumen-protected choline chloride.

The pregnant ewes model is suitable for human nutrition research, particularly pregnant women suffering from malnutrition (16,17). This study hypothesises that a metabolomics approach would extend our understanding of changes in urine metabolites in malnutrition and further that glycerol or rumen-protected choline chloride would improve a metabolic disorder in advanced pregnant ewes suffering from malnutrition. Thus, the aim of the present study is to explore the metabolic profiles of pregnancy malnutrition induced by feed restriction (FR) and the counteracting effects of glycerol and rumen-protected choline chloride supplementation.

Materials and methods

The experimental design and procedures of this study have been approved by the Animal Care and Use Committee of Nanjing Agricultural University following the requirements of the Regulations for the Administration of Affairs Concerning Experimental Animals (The State Science and Technology Commission of People's Republic of China, 1988. No. SYXK(Su)2015-0656).

Animals and experimental design

The first experiment is a continuation of previous research, where the malnutrition and lipid metabolism disorder in livers of ewes were induced by FR⁽¹⁸⁾. Briefly, twenty pregnant Hu sheep (body weight 60.6 (sp 4.9) kg) carrying multiple fetuses with similar parity (2-3 parity) and a gestation period of 108 d were randomly divided into two groups after 7 d of adaption period. Each treatment group had ten replicated pens, and each pen had one ewe. The ewes in the control (CON) group were offered 100% of their nutritional requirements as recommended by National Research Council (1.56 kg total mixed ration, DM basis), while the FR group was offered 30 % of feed intake of the CON for 15 d. The ewes were maintained in individual pens $(2 \times 2 \text{ m})$ with free access to water and in good health condition and were fed twice daily at 08.00 and 17.00 hours. The ingredients and chemical compositions of the total mixed ration in the first experiment are summarised in online Supplementary Table S1. The ambient temperature was maintained at 12-18°C, and the living environment was in accordance with animal welfare guidelines.

To explore the counteracting effects of glycerol and rumenprotected choline chloride supplementation on the malnutrition in advanced pregnant ewes suffering from malnutrition, the second experiment was designed. Eighteen pregnant Hu sheep (body weight 67.7 (sp 7.7) kg) with similar parity (2-3 parity) and a gestation period of 100 d were offered a feed intake comprising 30% of the National Research Council-recommended nutritional requirements twice daily and had free access to water. Each treatment group had six replicated pens, and each pen had one ewe. The sheep were randomly divided into three groups: the feed restriction (FR2) group with no supplementation, the glycerol (GLY) group, which received 40 ml of glycerol (Nanjing Yunbo Chemical Co. Ltd) per d, and the rumen-protected choline chloride (RPC) group, which received 10 g of rumen-protected choline chloride (Hangzhou King Technology Feed Co. Ltd) per d. These dose of supplements were in accordance with previous studies^(19,20). The supplements were mixed with a portion of the morning diet to make sure the ewes consume all the supplements. The remaining diet was then provided to the ewes after consuming the first portion. The ewes were maintained in individual pens $(2 \times 2 \text{ m})$ and in good health condition and were fed twice daily at 08.00 and 17.00 hours. The ingredients and chemical compositions of the total mixed ration in the second experiment are summarised in online Supplementary Table S2. Supplements were given during morning feedings over a 9-d period. The ambient temperature was maintained at 12-18°C, and the living environment was in accordance with animal welfare guidelines.

Sampling procedures

On the 15th d of the first experiment, all the ewes were slaughtered 4 h after morning feeding. Instead of collecting liver samples as done in other studies, urine samples were collected only

once from the bladder. On the ninth day of the second experiment, a sterile sponge was fixed to the urethral orifice of the ewe by a rope before morning feeding. The sponges were collected from each ewe within 4 h when the sponges were wet. This collection of urine samples was done once, and all the collected urine samples were stored in liquid N_2 prior to analysis.

Liquid chromatography-MS analysis

Eight urine samples from ewes in each group were randomly selected in the first experiment, and all the ewes' urine samples in the second experiment were used for metabolomics analysis. One hundred microlitres of the urine samples was mixed with 0·3 ml of methanol and 10 μ l ι -2-chlorophenylalanine (interior label), and the mixture was vortexed for 30 s and then centrifuged at 13 800 ${\it g}$ for 10 min at 4°C. Two hundred microlitres of the supernatant was transferred to the injection vial. Four microlitres of urine samples were injected into the liquid chromatography-MS (LC/MS) system (Thermo, Ultimate 3000LC, Orbitrap Elite) with an Agilent C18 column (Hypergod C18, 100 mm × 4·6 mm × 3 μ m) and maintained at 40°C.

The mobile phases A and B used water with 0·1 % (v/v) formic acid and acetonitrile with 0·1 % (v/v) formic acid with a flow rate of 0·3 ml/min. The elution procedure was 5 % B for 0–2 min, 5–95 % B for 2–12 min, 95 % B for 12–15 min and 95–5 % B for 15–17 min. MS was operated in either positive or negative ion mode. N₂ was used as nebuliser gas with a flow rate of 8 litres/min, scan time of 0·03 s, interscan time of 0·02 s and scan range of 50–1000 *m/z*. Parameters for positive ion mode were as follows: heater temperature 300°C, sheath gas flow rate 45 arb, aux gas flow rate 15 arb, sweep gas flow rate 1 arb, spray voltage 3·0 KV, capillary temperature 350°C and S-Lens RF level 30 %. Parameters for negative ion mode were as follows: heater temperature 300°C, sheath gas flow rate 45 arb, aux gas flow rate 15 arb, sweep gas flow rate 1 arb, spray voltage 3·2 kV, capillary temperature 350°C and S-Lens RF level 60 %.

The raw data were preprocessed by SIEVE software (ThermoFisher Scientific) for LC/MS data where parameters were as follows: intensity threshold, 100 000; m/z range, 50–1000; m/zwidth, 10 ppm; frame time width, 0.5 min; retention time start and end values were 0.01-20 min, respectively. Then, they were normalised according to the interior label and post-edited in EXCEL 2010 software. The Kyoto Encyclopedia of Genes and Genomes Database (http://www.genome.jp/kegg) and the online Human Metabolome Database (http://www.hmdb.ca) were used to align the molecular mass data to identify metabolites, and a retention time index was used in the analysis. When the difference between theoretical mass and observed mass was <10 ppm, the metabolite would be reported and further validated by isotopic distribution measurement. Commercial reference standards were utilised to validate and confirm the urine metabolites with high confidence by comparison of their MS/MS spectra and retention time. The principal component analysis (PCA) and partial least squares-discriminate analysis (PLS-DA) were carried out in SIMCA-P software (Umetrics). Differentially expressed metabolites were identified according to variable importance in projection >1 and adjusted P < 0.05, which were obtained from PLS-DA and statistical analysis,

respectively. The concentration table of differentially expressed metabolites was then imported in the module of 'pathway analysis' in website of MetaboAnalyst 4.0 (http://www.metaboanalyst.ca) for pathway enrichment analysis. The number of sheep per group were calculated by G*Power 3.1.9.4 assuming a hypothesised effect size F of 0.9, a type I error of 0.05 (two sided) and a statistical power of 0.80, based on F test using oneway ANOVA.

Results

Glucose and β-hydroxybutyric acid concentrations

During the whole experimental period, there were no adverse events. The blood concentrations of glucose and β -hydroxybutyric acid (BHBA) in the first experiment have been published and are shown in online Supplementary Fig. S1(A) and (B). In summary, FR increased blood BHBA concentration (P < 0.001) and decreased blood glucose concentration (P < 0.001) in advanced pregnant ewes. The second experiment revealed that glycerol and RPC prevented a decrease in blood glucose concentration (P = 0.010) and an increase in blood BHBA concentration (P < 0.001) (online Supplementary Fig. S1(C) and (D), under review).

Liquid chromatography/MS compound identification and quantification

In total, LC/MS detected 431 and 445 unique and non-overlapping valid peaks in the urine samples of the first and second experiments, respectively. A total of 268 and 240 metabolites were identified and quantified in the first and second experiments, respectively.

Multivariate analysis

In the first experiment, the PLS-DA model explained $95.7 \% (R^2 Y)$ and predicted $89.2\%(Q^2)$ of the data. In the second experiment, the PLS-DA model explained 64.7% (R^2Y) and predicted 68.2% (Q^2) of the data when comparing the FR2 and GLY groups, while it explained 60 % (R^2Y) and predicted 62 % (Q^2) of the data when comparing the FR2 and RPC groups. These results indicated that the PLS-DA was an adequate model. The PCA and PLS-DA showed clear separation between the CON group and FR group in the first experiment (Fig. 1(a) and (b)) and among the FR2, GLY and RPC groups in the second experiment (Fig. 2(a)-(c)), indicating that there was a noticeable difference in urine metabolites between the CON and FR groups and among the FR2, GLY and RPC groups. In the first experiment, the first and second principal components of the PCA score plot accounted for 39.3 and 15·1 % of the variation, respectively (Fig. 1(a)), while PLS axis 1 explained 38.8 % and axis 2 explained 12.5 % of the variation, as shown in Fig. 1(b). In the second experiment, the first principal component of the PCA score explained 41.7 %, while the second one explained 23.9 % of the variation (Fig. 2(a)). The score plots of PLS-DA showed that PLS axes 1 and 2 explained 44.8 and 24.3% of the variation, respectively, for the GLY and FR2 groups (Fig. 2(b)), and 33.0 and 27.2 % of the variation for the RPC and FR2 groups, respectively (Fig. 2(c)). One dot represents one








Fig. 1. (a) Principal component analysis (PCA) and (b) partial least squares-discriminate analysis (PLS-DA) scores plot of urine metabolites based on liquid chromatography/MS from control (CON) and feed restriction (FR) groups. CON, offered 100 % of their National Research Council recommended nutritional requirements; FR, restricted to 30 % of feed intake of CON. ●, CON; ■, FR.

PC1 = 39·3 %




Fig. 2. (a) Principal component analysis (PCA) scores plot of urine metabolites based on liquid chromatography (LC)/MS from the feed restriction group in the second experiment (FR2), glycerol (GLY) group and rumen-protected choline chloride (RPC) group. (b) Partial least squares-discriminate analysis (PLS-DA) scores plot of urine metabolites based on LC/MS from GLY and FR2 groups. (c) PLS-DA scores plot of urine metabolites based on LC/MS from RPC and FR2 groups. FR2, offered 30 % of the National Research Council (NRC)-recommended nutritional requirements; GLY, offered 30 % of the NRC-recommended nutritional requirements and received 40 ml of glycerol per d; RPC, offered 30 % of the NRC-recommended nutritional requirements and received 10 g of RPC per d. (a) 🔵, FR2; 🌏, GLY; 🌏, RPC; (b) 🧓, FR2; 📕, GLY; (c) •, FR2; ■, RPC.

observation sample, and the distance between two dots represents the similarity of the sample's metabolite composition. In the present study, the PCA and PLS-DA revealed clear separations in urine metabolites between CON and FR groups (Fig. 1(a) and (b)). There was also clear distinction among the groups of FR2, GLY and RPC groups (Fig. 2(a)-(c)).

Identification of different metabolites

Based on the criteria (variable importance in projection > 1 and corrected P < 0.05), there were 135 differentially expressed metabolites between the CON and FR groups (Table 1) in the first experiment. In the second experiment, there were thirty-three and thirty metabolites affected by GLY (Table 2) and RPC

PLS1 = 38.8 %

Table 1. Identification of significantly different metabolites in urine between ewes from control (CON) and feed restriction (FR) groups

Metabolites	VIP	Fold change	Adjusted P
Carbohydrates			
D-Glucose	1.45	0.05	0.000
Lactic acid	1.32	0.46	0.001
Levoglucosan Oxalosuccinic acid	1·13 1·34	0·35 10·04	0.007
α -Ketoglutarate	1.31	0.40	0·000 0·001
Phosphohydroxypyruvic acid	1.32	0.40	0.001
Pyruvate	1.14	21.30	0.021
Sedoheptulose 8-phosphate	1.07	2.76	0.003
D-Glucoside	1.32	0.22	0.001
D-Ribose	1.25	1.76	0.007
Fumaric acid	1.34	2.29	0.001
Gluconic acid	1.26	1.77	0.007
Glucose 6-phosphate	1.26	0.37	0.007
∟-Fucose 1-phosphate	1.17	0.22	0.007
Oxaloglutarate	1.26	0.47	0.005
Raffinose Sedoheptulose 7-phosphate	1.35 1.26	0·43 0·45	0·005 0·000
Fatty acids and lipids	1.20	0.45	0.000
Nervonyl carnitine	1.19	1.05	0.003
L-Octanoylcarnitine	1.34	4.21	0.000
Ketoisovaleric acid	1.20	1.11	0.010
11-Deoxy PGF2	1.39	0.26	0.001
13(S)-HpOTrE	1.23	0.51	0.007
15d-PGA1	1.13	0.45	0.007
15d-PGA2	1.00	3.88	0.007
Acetoacetic acid	1.51	5.13	0.000
Acetylcarnitine	1.31	4.45	0.000
Acetylcholine	1.13	0.66	0.007
Butyryl-L-carnitine	1.20	4.83	0.005
Decanoyl-L-carnitine Decenedioic acid	1.03 1.20	217·21 4·57	0.001 0.000
Eicosatrienoic acid	1.33	0.37	0.000
PA (19:3 (10Z,13Z,16Z)/0:0)	1.07	5·32	0.002
PA (20:0/0:0)	1.28	1.20	0.000
PA (O-18:0/19:1 (9Z))	1.09	0.13	0.005
Phosphocholine	1.42	0.29	0.000
Phosphorylcholine	1.44	0.23	0.000
PA (14:0/0:0)	1.01	7.11	0.000
PA (20:3 (8Z,11Z,14Z)/0:0)	1.06	4.77	0.002
PA (22:6	1.10	2.48	0.007
(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)	1 10	4.57	0.000
PA (6:0/6:0) PC (P-18:1 (9Z)/0:0)	1·13 1·15	4·57 0·15	0.003
PG (12:0/0:0)	1.26	0.13	0.018 0.002
PG (18:1 (9Z)/0:0)	1.30	0.51	0.002
PG (O-18:0/17:0)	1.29	0.29	0.001
PG (O-18:0/17:2 (9Z,12Z))	1.46	0.39	0.002
PGÀ1	1.39	0.09	0.000
PGK2	1.41	0.01	0.000
Undecanedioic acid	1.19	0.57	0.005
2-Hydroxycinnamic acid	1.38	0.47	0.002
3-Phenylacetamide	1.48	0.52	0.000
4-Hydroxydodecanedioic acid	1.35	4.73	0.000
5(S)-HETE	1.26	7.60	0.007
6-Keto-PGF1	1.13	1.22	0.003
Acetone β-Hydroxybutyric acid	1.42 1.34	0·22 22·92	0.000 0.000
Chenodeoxycholic acid 3-sulfate	1.41	3·15	0.000
CPA (18:2 (9Z,12Z)/0:0)	1.17	0.57	0.000
Gentisic acid	1.36	3.40	0.000
Hexadecanedioic acid	1.45	0.36	0.000
L-Hexanoylcarnitine	1.19	4.32	0.007
LPA (0:0/18:0)	1.43	0.11	0.000
LysoPC (22:6	1.00	2.56	0.021
(4Z,7Z,10Z,13Z,16Z,19Z))			
MG (0:0/16:1 (9Z)/0:0)	1.36	1.76	0.000

Table 1. (Continued)

Metabolites	VIP	Fold change	Adjusted F
MG (0:0/20:4 (5Z,8Z,11Z,14Z)/0:0)	1.16	0.21	0.002
MG (0:0/22:1 (13Z)/0:0)	1.11	0.26	0.001
MG (16:0/0:0/0:0)	1.12	0.02	0.001
PS (O-16:0/0:0)	1.09	1.12	0.015
Stearamide	1.32	59-20	0.001
Stearidonic acid	1.61	3.56	0.000
α -Tocotrienol	1.24	0.71	0.015
β -Hydroxyisovaleric acid	1.56	3.39	0.000
Amino acids			
Nitrotyrosine	1.16	5.26	0.015
N-methylhistamine	1.22	11.28	0.000
Ornithine N-acetyl-DL-methionine	1.45 1.48	0·39 0·43	0.001 0.000
N-acetyl-DL-tryptophan	1.46	0.43	0.000
L-Theanine	1.31	3.53	0.007
L-Homophenylalanine	1.38	0.31	0.001
L-Arginine	1.32	0.22	0.000
L-Asparagine	1.27	0.50	0.001
Ketoleucine	1.28	1.69	0.003
Glutamate	1.08	0.16	0.007
Histidine	1.04	0.54	0.003
Homoarginine	1.23	2.78	0.007
Homogentisic acid	1.36	3.40	0.000
DL-2-Amino-octanoic acid	1.13	7.12	0.000
2-Phenylacetamide	1.41	0.51	0.000
3-Hydroxy-L-proline	1.38	1.63	0.000
3-Indolepropionic acid	1.35	0.19	0.000
Alanine	1.13	0.44	0.001
Cinnamic acid	1.09	0.41	0.015
Cysteine	1.26	3.55	0.001
Proline betaine	1.30	0.39	0.000
Pyroglutamic acid Threonine	1·34 1·17	9·17 1·14	0.000
Trimethylaminoacetone	1.17	0.25	0.003 0.000
Tyrosine	1.30	0.23	0.000
Urea	1.37	140-68	0.000
Urocanic acid	1.37	2.64	0.001
Aspartic acid	1.22	11.41	0.000
Creatinine	1.17	0.43	0.021
D-Leucic acid	1.21	1.68	0.005
Glutathione	1.41	0.35	0.002
Homocysteine	1.38	0.29	0.003
Leucinic acid	1.53	2.96	0.000
L-Lysine	1.22	0.38	0.003
Metyrosine	1.30	7.40	0.002
Valine	1.26	4.95	0.000
Others			
4-Aminophenol	1.10	0.36	0.007
Anthranilic acid	1.29	0.49	0.001
Caffeic acid	1.31	62.46	0.005
Hydrouracil (dihydrothymine)	1.17	0.47	0.005
Hydroxyphenyllactic acid	1.26	0.32	0.002
Indole Indolelactic acid	1.06	0·10 251·29	0.000
Indoleiactic acid	1.08 1.47	0.07	0.001 0.000
KAPA	1.47	1.42	0.000
L-Ascorbic acid	1.35	0.30	0.000
Pantothenic acid	1.26	0.49	0.000
Pyridoxine	1.28	0.54	0.001
Thiamine	0.98	2.44	0.010
Uridine	1.46	0.22	0.000
Urocortisol	1.50	1.11	0.000
Bilirubin	1.02	68-67	0.001
Corticosterone	1.19	0.38	0.007
Cortisol	1.13	212.93	0.000
Glymidine	1.28	2.42	0.007
Levonorgestrel	1.31	1.27	0.001





Table 1. (Continued)

Metabolites	VIP	Fold change	Adjusted P
Octylamine	1.38	6.49	0.001
Phenylacetic acid	1.20	0.48	0.015
Riboflavin (vitamin B ₂)	1.24	0.15	0.002
Ricinoleic acid	1.24	1.85	0.001
Salicylic acid	1.35	0.19	0.000
Ubiquinone-1	1.37	0.47	0.002
Xanthoxic acid	1.18	0.47	0.010

CON, offered 100 % of their National Research Council recommended nutritional requirements; FR, restricted to 30 % of feed intake of CON; VIP, variable importance in projection; fold change, mean peak area of FR group/mean peak area of CON group.

Table 2. Identification of significantly different metabolites in urine between ewes from the glycerol (GLY) group and feed restriction group in the second experiment (FR2)

Metabolites	VIP	Fold change	Adjusted P
Glucose-6-phosphate	1.02	985-36	0.037
S-acetyldihydrolipoamide-E	1.03	123.78	0.024
N2-methylguanine	1.01	47.75	0.029
MG (12:0/0:0/0:0)	1.12	47.63	0.028
N-acetylserotonin	1.40	27.43	0.047
12,13-DHOME	1.12	8.34	0.023
L-Phenylalanine	1.10	6.90	0.027
Indoleacetic acid	1.72	6.60	0.010
Isovalerylglycine	1.08	6.37	0.007
Acetylcysteine	1.13	5.60	0.036
N-phenylacetylglutamic acid	1.35	5.49	0.043
Homo-L-arginine	1.01	4.89	0.006
Malic acid	1.03	4.70	0.024
Citric acid	1.04	4.65	0.038
α-Ketoglutarate	1.09	3.98	0.040
Hydroxyphenyllactic acid	1.23	3.94	0.045
L-Tyrosine	1.30	3.53	0.009
L-Proline	1.12	3.34	0.001
Hydroxyphenylacetylglycine	1.74	3.21	0.036
N-acetyl-DL-tryptophan	1.41	3.10	0.001
4-Hydroxybenzaldehyde	1.02	2.66	0.038
Succinic acid	1.45	2.46	0.023
Norepinephrine	1.10	2.35	0.045
Oxoadipic acid	1.10	2.30	0.011
Valerylglycine	1.24	2.26	0.021
Cholic acid	1.34	0.39	0.018
3-Dehydroxycarnitine	1.45	0.30	0.006
Hydroxyoctanoic acid	1.56	0.12	0.014
Sebacic acid	1.15	0.10	0.022
7-Ketodeoxycholic acid	1.26	0.06	0.028
L-Octanoylcarnitine	1.20	0.06	0.004
Glutaconylcarnitine	1.26	0.01	0.005
D-Glucose	1.08	1.24	0.043

GLY, offered 30 % of the National Research Council (NRC)-recommended nutritional requirements and received 40 ml of glycerol per d: FR2, offered 30 % of the NRCrecommended nutritional requirements: VIP, variable importance in projection; fold change, mean peak area of GLY group/mean peak area of FR2 group.

(Table 3), respectively, as compared with the FR2 group. In general, the different metabolites in this study were mainly involved in carbohydrates, amino acid and fatty acids metabolism. Specifically, compared with the CON group, FR decreased the level of D-glucose, lactic acid, levoglucosan, α -ketoglutarate, phosphohydroxypyruvic acid and glucose 6-phosphate, while increased the level of pyruvate and fumaric acid in urine. For different metabolites involved in lipid metabolism, all the

Table 3. Identification of significantly different metabolites in urine between ewes from the rumen-protected choline chloride (RPC) group and feed restriction group in the second experiment (FR2)

2-Ketoglutarate 1.24 2.42 0.0 2-Phenylglycine 1.58 5.15 0.0 3-Hexenoic acid 1.28 4.70 0.0 3-Hydroxybutyrate 1.09 0.45 0.0 5Z-dodecenoic acid 1.58 4.47 0.0 7-Ketodeoxycholic acid 1.66 7.43 0.0 Acetylcholine 1.10 3.00 0.0 Adenosine 1.41 5.51 0.0 Carnosine 1.36 7.76 0.0 Creatine 1.32 2.68 0.0 Cytosine 1.36 4.59 0.0 Decenedioic acid 1.67 3.16 0.0 Hydrocinnamic acid 1.67 2.70 0.0 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylcarnitine 1.98 3.12 0.0 L-Acetylcarnitine 1.02 0.37 0.0 L-Carnitine 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 1.06 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.0 N(6)-methyllysine 1.50 3.47 0.00	ed P
3-Hexenoic acid 1.28 4.70 0.00 3-Hydroxybutyrate 1.09 0.45 0.00 5Z-dodecenoic acid 1.58 4.47 0.00 7-Ketodeoxycholic acid 1.66 7.43 0.0 Acetylcholine 1.10 3.00 0.0 Adenosine 1.41 5.51 0.00 Carnosine 1.36 7.76 0.00 Creatine 1.32 2.68 0.00 Cytosine 1.36 4.59 0.00 Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.00 Hydrocinnamic acid 1.67 2.70 0.0 Hydrocinnamic acid 1.67 2.70 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylcarnitine 1.02 0.37 0.00 L-Acetylcarnitine 1.47 3.35 0.00 L-Carnitine 1.47 3.35 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.00 MG (0:0/15:0/0:0) 1.06 0.89 0.00 MG (0:0/16:0/0:0) 0.55 0.84	—— 30
3-Hydroxybutyrate 1.09 0.45 0.00 5Z-dodecenoic acid 1.58 4.47 0.00 7-Ketodeoxycholic acid 1.66 7.43 0.0 Acetylcholine 1.10 3.00 0.00 Adenosine 1.41 5.51 0.00 Creatine 1.36 7.76 0.00 Creatine 1.36 7.76 0.00 Creatine 1.36 4.59 0.00 Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.00 Hydrocinnamic acid 1.67 2.70 0.0 Hydrocinnamic acid 1.67 2.70 0.0 Isovalerylcarnitine 1.03 0.93 0.00 Isovalerylcycine 1.98 3.12 0.00 Isovalerylcycine 1.98 3.12 0.00 L-Acetylcarnitine 1.02 0.37 0.00 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.00 MG (0:0/15:0/0:0) 0.84 0.89 0.00 MG (0:0/15:0/0:0) 0.55 0.84 0.00 MG (0:0/16:0/0:0)	26
5Z-dodecenoic acid 1.58 4.47 0.00 7-Ketodeoxycholic acid 1.66 7.43 0.0 Acetylcholine 1.10 3.00 0.0 Adenosine 1.41 5.51 0.0 Carnosine 1.36 7.76 0.0 Creatine 1.32 2.68 0.00 Cytosine 1.36 4.59 0.00 Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.0 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.0 L-Acetylcarnitine 1.02 0.37 0.0 L-Proline 1.38 4.55 0.0 L-Proline 1.38 4.55 0.0 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 <t< td=""><td>31</td></t<>	31
7-Ketodeoxycholic acid 1-66 7-43 0-0 Acetylcholine 1-10 3-00 0-0 Adenosine 1-41 5-51 0-0 Carnosine 1-36 7-76 0-0 Creatine 1-32 2-68 0-0 Cytosine 1-36 4-59 0-0 Decenedioic acid 1-51 3-16 0-0 Dodecanedioic acid 1-51 3-16 0-0 Hydrocinnamic acid 1-67 2-70 0-0 Hypoxanthine 1-74 3-69 0-0 Isovalerylcarnitine 1-03 0-93 0-0 Isovalerylglycine 1-98 3-12 0-0 L-Acetylcarnitine 1-02 0-37 0-0 L-Carnitine 1-47 3-35 0-0 L-Proline 1-38 4-55 0-0 L-Tyrosine 1-69 3-13 0-0 LysoPA (8:0/0:0) 0-84 0-89 0-0 MG (0:0/15:0/0:0) 1-06 0-89 0-0 MG (0:0/16:0/0:0) 0-55 0-84	16
Acetylcholine 1.10 3.00 0.0 Adenosine 1.41 5.51 0.0 Carnosine 1.36 7.76 0.0 Creatine 1.32 2.68 0.0 Cytosine 1.36 4.59 0.0 Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.0 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.0 L-Acetylcarnitine 1.02 0.37 0.0 L-Proline 1.38 4.55 0.0 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 0.05 0.05 0.84 0.0	21
Adenosine 1.41 5.51 0.00 Carnosine 1.36 7.76 0.00 Creatine 1.32 2.68 0.00 Cytosine 1.36 4.59 0.00 Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.00 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.00 Isovalerylglycine 1.98 3.12 0.00 L-Acetylcarnitine 1.02 0.37 0.00 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 0.05 0.04 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.00	19
Carnosine 1.36 7.76 0.00 Creatine 1.32 2.68 0.00 Cytosine 1.36 4.59 0.00 Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.00 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.00 L-Acetylcarnitine 1.02 0.37 0.00 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 1.06 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.00	16
Creatine 1.32 2.68 0.00 Cytosine 1.36 4.59 0.00 Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.00 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.00 L-Acetylcarnitine 1.02 0.37 0.00 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 1.06 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.00	18
Cytosine 1.36 4.59 0.00 Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.00 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.00 L-Acetylcarnitine 1.02 0.37 0.00 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 0.05 0.84 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.00	26
Decenedioic acid 1.51 3.16 0.0 Dodecanedioic acid 1.81 3.19 0.00 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.0 L-Acetylcarnitine 1.02 0.37 0.00 L-Camitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 1.06 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.00	38
Dodecanedioic acid 1.81 3.19 0.00 Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.0 L-Acetylcarnitine 1.02 0.37 0.0 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 1.06 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.00)3
Hydrocinnamic acid 1.67 2.70 0.0 Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.0 L-Acetylcarnitine 1.02 0.37 0.0 L-Carnitine 1.47 3.35 0.0 L-Proline 1.38 4.55 0.0 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 1.06 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.0	11
Hypoxanthine 1.74 3.69 0.0 Isovalerylcarnitine 1.03 0.93 0.0 Isovalerylglycine 1.98 3.12 0.0 L-Acetylcarnitine 1.02 0.37 0.0 L-Carnitine 1.47 3.35 0.0 L-Proline 1.38 4.55 0.0 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 1.06 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.0	25
Isovalerylcarnitine 1.03 0.93 0.00 Isovalerylglycine 1.98 3.12 0.00 L-Acetylcarnitine 1.02 0.37 0.00 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.00 MG (0:0/15:0/0:0) 1.06 0.89 0.00 MG (0:0/16:0/0:0) 0.55 0.84 0.00	11
Isovalerylglycine 1.98 3.12 0.00 L-Acetylcarnitine 1.02 0.37 0.00 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.00 MG (0:0/15:0/0:0) 1.06 0.89 0.00 MG (0:0/16:0/0:0) 0.55 0.84 0.00	13
L-Acetylcarnitine 1.02 0.37 0.00 L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.00 MG (0:0/15:0/0:0) 1.06 0.89 0.00 MG (0:0/16:0/0:0) 0.55 0.84 0.00	19
L-Carnitine 1.47 3.35 0.00 L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.00 MG (0:0/15:0/0:0) 1.06 0.89 0.00 MG (0:0/16:0/0:0) 0.55 0.84 0.00	32
L-Proline 1.38 4.55 0.00 L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.00 MG (0:0/15:0/0:0) 1.06 0.89 0.00 MG (0:0/16:0/0:0) 0.55 0.84 0.00	29
L-Tyrosine 1.69 3.13 0.0 LysoPA (8:0/0:0) 0.84 0.89 0.00 MG (0:0/15:0/0:0) 1.06 0.89 0.00 MG (0:0/16:0/0:0) 0.55 0.84 0.00	39
LysoPA (8:0/0:0) 0.84 0.89 0.0 MG (0:0/15:0/0:0) 1.06 0.89 0.0 MG (0:0/16:0/0:0) 0.55 0.84 0.0	22
MG (0:0/15:0/0:0) 1.06 0.89 0.00 MG (0:0/16:0/0:0) 0.55 0.84 0.00	14
MG (0:0/16:0/0:0) 0.55 0.84 0.0	50
	17
N(6)-methyllysine 1.50 3.47 0.00	1 7
	27
N-acetylhistidine 1.29 2.59 0.00	36
Proline betaine 1.57 3.12 0.0	14
Propenoylcarnitine 1.46 0.25 0.0	13
Tyrosol 1.33 3.06 0.0	16
Valerylglycine 1.27 2.81 0.00	39

RPC, offered 30 % of the National Research Council (NRC)-recommended nutritional requirements and received 10 g of rumen-protected choline chloride (RPC) per d; FR2. offered 30 % of the NRC-recommended nutritional requirements: VIP, variable importance in projection; fold change, mean peak area of RPC group/mean peak area of FR2 group.

carnitines, six species of phosphatidic acid (PA), all the phosphatidylglycerol (PG), one species of monoacylglycerol (MG), three species of fatty acid, including nervonyl carnitine, L-octanoylcarnitine acetylcarnitine, butyryl-L-carnitine, decanoyl-1-carnitine, 1-hexanoylcarnitine, PA (19: 3 (10Z,13Z,16Z)/ 0:0), PA (20:0/0:0), PA (14:0/0:0), PA (20:3(8Z,11Z,14Z)/0:0), PA (22:6 (4Z,7Z,10Z,13Z,16Z,19Z)/0:0), PA (6:0/6:0), PG (12:0/0:0), PG (18:1 (9Z)/0:0), PG (O-18:0/17:0), PG (O-18: 0/17: 2 (9Z,12Z)), MG (0: 0/16: 1 (9Z)/0: 0), decenedioic acid, 4-hydroxydodecanedioic acid and stearidonic acid were significantly increased, while only one species of PA, three species of MG, all the methyl donors and three species of fatty acids, including PA (O-18:0/19:1 (9Z)), proline betaine, acetylcholine, phosphocholine, phosphorylcholine, MG(0:0/20:4(5Z,8Z,11Z,14Z)/0:0), MG(0:0/22:1(13Z)/0:0)0:0), MG (16:0/0:0/0:0), eicosatrienoic acid, undecanedioic acid and hexadecanedioic acid were decreased in the FR group than in the CON group.

For different metabolites involved in amino acid metabolism, the ketogenic compounds (leucine and lysine) and the glycogenic amino acid (including alanine, cysteine, valine and aspartic acid) were increased, while the glycogenic amino acids (including glutamate, histidine, arginine,






Fig. 3. Metabolome view map of the differentially expressed metabolites identified in the ewes' urine between the control (CON) and feed restriction (FR) groups. The CON group was offered 100 % of their National Research Council recommended nutritional requirements; the FR group was restricted to 30 % of feed intake of CON. The larger size indicates higher pathway enrichment, and the darker colour indicates higher pathway impact values.

tyrosine and asparagine) were decreased in the FR group rather than the CON group.

In the second experiment, compared with the FR2 group, supplementing glycerol increased the levels of D-glucose, glucose-6-phosphate, malic acid, citric acid, α -ketoglutarate, succinic acid, L-tyrosine, L-proline and norepinephrine, while decreased the levels of 3-dehydroxycarnitine, L-octanoylcarnitine, glutaconylcarnitine, cholic acid and 7-ketodeoxycholic acid. Compared with the FR2 group, supplementing RPC increased the levels of proline betaine, acetylcholine, L-carnitine, decenedioic acid, L-proline, L-tyrosine and 2-ketoglutarate, while decreasing the levels of isovalerylcarnitine, LysoPA (8:0/0:0), MG (0:0/15:0/0:0), MG (0:0/16:0/0:0), BHBA, L-acetylcarnitine and propenoylcarnitine.

To comprehensively explore how the pathways changed in response to FR, glycerol and RPC, pathway enrichment analysis was performed based on various metabolites (Figs. 3–5). Through pathway topology analysis, the pathway was selected when the pathway impact value was higher than 0.1, which is the cut-off value for relevance. The pathway with its P value and impact value is listed in Table 4.Finally, to more intuitively observe metabolic profiles in malnutrition and the effect of glycerol or RPC on it, a metabolic network map was performed (Fig. 6).

Discussion

Urine metabolome alterations in malnutrition

The first objective of this study was to explore the changes in the urine metabolome in advanced pregnant ewes suffering from




Fig. 4. Metabolome view map of the differentially expressed metabolites identified in the ewes' urine between the glycerol (GLY) group and feed restriction group in the second experiment (FR2). GLY, offered 30% of the National Research Council (NRC)-recommended nutritional requirements and received 40 ml of glycerol per d; FR2, offered 30% of the NRC-recommended nutritional requirements. The larger size indicates higher pathway enrichment, and the darker colour indicates higher pathway impact values. TCA, tricarboxylic acid.

malnutrition. Previously, we discovered that malnutrition caused by FR resulted in lipid metabolism disorder in livers in pregnant ewes⁽¹⁸⁾. In the present study, we attempted to explore the global metabolic profiles in urine based on LC/MS metabolomics. In this study, PCA and PLS-DA revealed a clear distinction between the








Fig. 5. Metabolome view map of the differentially expressed metabolites identified in the ewes' urine between the rumen-protected choline chloride (RPC) group and feed restriction group in the second experiment (FR2). RPC, offered 30 % of the National Research Council (NRC)-recommended nutritional requirements and received 10 g of RPC per d. FR2, offered 30 % of the NRC-recommended nutritional requirements. The larger size indicates higher pathway enrichment, and the darker colour indicates higher pathway impact values.

Table 4. Enriched pathways based on differentially expressed metabolites in different treatments

Pathway	P	Impact value
CON v. FR group		
D-Glutamine and D-glutamate metabolism	0.204	1.000
Synthesis and degradation of ketone bodies	0.018	0.600
Histidine metabolism	0.003	0.525
Phenylalanine, tyrosine and tryptophan biosynthesis	0.167	0.500
Alanine, aspartate and glutamate metabolism	0.017	0.427
Glutathione metabolism	0.026	0.420
Arginine and proline metabolism	0.042	0.224
Tyrosine metabolism	0.113	0.145
Cysteine and methionine metabolism	0.725	0.128
Butanoate metabolism	0.056	0.101
GLY v. FR2 group		
Phenylalanine, tyrosine and tryptophan biosynthesis	0.001	1.000
Phenylalanine metabolism	0.011	0.407
Glyoxylate and dicarboxylate metabolism	0.262	0.296
Tyrosine metabolism	0.184	0.259
Citrate cycle (TCA cycle)	<0.001	0.221
Pyruvate metabolism	0.342	0.161
Starch and sucrose metabolism	0.067	0.149
Starch and sucrose metabolism RPC <i>v.</i> FR2 group	0.083	0.102
Phenylalanine, tyrosine and tryptophan biosynthesis	0.054	0.500
Tyrosine metabolism	0.444	0.145

CON, control group; FR, feed restriction; GLY, glycerol group; FR2, FR in the second experiment: RPC, rumen-protected choline chloride.

CON and FR groups, indicating there was significant difference between the two groups, which was consistent with previous research that showed the metabolic condition would shift to catabolism from anabolism during NEB⁽²¹⁾.

The body undergoes mobilisation of body reserves to support a balance of blood glucose. Lipids are physiological fuels with low water content and high energy density⁽²²⁾. In the present study, some fatty acids and all the carnitines in the urine increased in malnutrition. Given that high level of NEFA that exists in ruminants during NEB and carnitines function as transporters of fatty acids into the mitochondria for subsequent β -oxidation⁽²³⁾, the results of this study indicated increased mobilisation and subsequent β -oxidation of fatty acids in malnutrition.

Interestingly, we found that the level of cortisol was 212-9fold greater in the FR group than that of the CON group. Cortisol has been proven to increase the hepatic and renal gluconeogenic enzyme activities, including glucose-6-phosphatase and aspartate transaminase⁽²⁴⁾. A large increase in cortisol level in this study indicates that ewes suffering from malnutrition responsively increase endogenous glucose production through endocrine regulation. However, in this study, we observed lower levels of phosphohydroxypyruvic acid and glucose 6-phosphate and an increased pyruvate level in the FR group compared with the CON group. Moreover, the concentration of blood glucose was still low, and the concentration of BHBA was still high (online Supplementary Fig. S1(A) and (B)). The reason may be attributed to a disorder in gluconeogenesis.

Specifically, it seems as if the process of pyruvic acid producing phosphohydroxypyruvic acid and subsequent glucose 6-phosphate was blocked. Because the pyruvic acid produces oxaloacetate and then enters the malate shuttle to produce phosphohydroxypyruvic acid, while the acetyl-CoA produced by β -oxidation of mobilised fatty acids should also combine with oxaloacetate and enter a TCA cycle to provide energy. Thus, the oxaloacetate deficiency was related to a disorder in the process of transforming pyruvic acid into oxaloacetate, resulting in the hinderance of acetyl-CoA from entering the TCA cycle. This speculation was evidenced by previous study which showed that supplementation of biotin, a cofactor of pyruvate carboxylase function as a catalyst of the reaction of transforming pyruvic acid into oxaloacetate, increased blood glucose concentration and decreased TAG and NEFA concentration in transition dairy cows during NEB⁽²⁵⁾.

In addition, the present study revealed that all the cholines (acetylcholine, phosphocholine and phosphorylcholine) and proline betaine decreased in the FR group. Betaine and cholines participate in the production of phosphorylcholine, which plays a key role in combining with TAG to synthesise VLDL⁽²⁶⁾. These results indicated excessive mobilisation of fatty acids and accumulation in the liver due to insufficient methyl donors. Given that potential drain of phosphorylcholine may impair lipid membrane integrity⁽²⁷⁾, the abnormal level of membrane lipid (PA and PG), D-ribose and inosine in the FR group probably indicated the increased cell apoptosis, as malnutrition could induce macrophage apoptosis and significantly host immunosuppression, resulting in increased morbidity and mortality⁽²⁸⁾.

In the present study, the ketogenic compounds (leucine and lysine) and the glycogenic amino acids (including alanine, cysteine, valine and aspartic acid) were increased, while the glycogenic amino acids (including glutamate, histidine, arginine, tyrosine and asparagine) were decreased in the FR group compared with the CON group. When the lipid level reaches critical






Fig. 6. Overview of energy metabolism alteration in response to feed restriction, glycerol and rumen-protected choline chloride (RPC). , Significant increased metabolites in former group compared with the latter group; , no difference; , decrease; CON, offered 100% of their National Research Council (NRC) recommended nutritional requirements; FR, restricted to 30% of feed intake of CON; FR2, offered 30% of the NRC-recommended nutritional requirements; GLY, offered 30% of the NRC-recommended nutritional requirements and received 40 ml of glycerol per d; RPC, offered 30% of the NRC-recommended nutritional requirements and received 10 g of RPC per d.

threshold, the physiological switch from lipid-dominated catabolism to protein-dominated catabolism⁽²²⁾ and the amino acids mobilised from muscles become important gluconeogenesis substrates in malnutrition⁽²⁹⁾. The increased ketogenic compounds (leucine and lysine) probably indicate that the high level of BHBA in the FR group feedback inhibited their synthesis from the ketogenic compounds.

The decreased glycogenic amino acids (including glutamate, histidine, arginine, tyrosine and asparagine) which could enter TCA cycle likely indicate that they were used to provide energy. However, some other glycogenic amino acids (including alanine, cysteine, valine and aspartic acid) were increased. The increase in the levels of alanine and cysteine may be partly explained by the rise in pyruvic acid discussed above. Other causes of elevated alanine likely relate to liver glucogenic function, as alanine and glutamine are primary precursors of glucose in the liver and kidney, respectively⁽³⁰⁾. In malnutrition, the gluconeogenesis in liver from alanine (an endergonic process) was replaced in the kidney and intestines (an exergonic process) from glutamine⁽³⁰⁾. In the present study, the increased level of alanine and decreased level of glutamine was consistent with this finding.

Effect of glycerol or rumen-protected choline chloride supplementation on profiles of urine metabolome in advanced pregnant ewes

The second aim of this study was to determine the effects of the supplementations on the urine metabolome in ewes suffering from malnutrition. Glycerol may participate in gluconeogenesis directly or indirectly⁽³¹⁾. Glycerol showed potential to stabilise the concentrations of blood glucose and BHBA (online Supplementary Fig. S1). In the present study, we attempted to investigate the changes in the urine metabolome in ewes

treated with FR. Compared with the FR2 group, supplementing glycerol increased the levels of D-glucose, glucose-6-phosphate, malic acid, citric acid, α -ketoglutarate and succinic acid, indicating increased gluconeogenesis in ewes receiving glycerol, which was consistent with a previous study in dairy cows⁽⁸⁾. Interestingly, the level of norepinephrine was 2·3-fold greater in the GLY group than in the FR2 group. Norepinephrine, one of the catecholamines, was involved in inhibiting insulin secretion, stimulating glucagon secretion and increasing the gluconeogenic substrate supply⁽³²⁾.

In addition, the pathway of citrate cycle (TCA cycle) (P < 0.001, impact value = 0.221) and glycolysis or gluconeogenesis (P = 0.083), impact value = 0.102) were also enriched when comparing the GLY group with the FR2 group. These results indicate that supplementing glycerol increased the TCA cycle and gluconeogenesis process by hormones, apart from being a precursor of glucose. In addition, we also found decreased levels of 3-dehydroxycarnitine, L-octanoylcarnitine, glutaconylcarnitine, cholic acid and 7-ketodeoxycholic acid in the GLY group, which could be attributed to its diminishment of fat mobilisation in the malnutrition discussed above.

Compared with the FR2 group, supplementing RPC increased the levels of proline betaine and acetylcholine. In line with previous studies, RPC and gastro-intestinal supplementation of choline and methionine up-regulated arterial levels of choline metabolites^(19,20). Although choline could be synthesised endogenously⁽³³⁾, the external choline was also required and the absence of choline, considered a lipotropic factor, could lead to fatty liver degeneration during the periparturient period and FR in dairy cows^(19,34,35). We also found increased levels of L-camitine and decreased levels of isovalerylcamitine, L-acetylcamitine, propenoylcamitine, MG (0:0/15:0/0:0) and MG (0:0/16:0/0:0). A previous study indicated that choline deficiency can increase





the serum carnitine level, decrease the tissue carnitine concentration, as well as the total body pool of carnitine and alter the carnitine turnover in $rats^{(36)}$.

Overview of energy metabolism alteration (Fig. 6) showed that, the significant decrease of glucose and glucose-6-phosphate levels was reversed by GLY but not RPC. However, both GLY and RPC reversed the increased BHBA level induced by FR. These results indicated the improved energy metabolism in the GLY and RPC groups when comparing with the FR2 group. The higher level of malic acid, α -ketoglutaric acid and glucose-6-phosphate in GLY group indicated that GLY improves NEB mainly by increasing gluconeogenesis, while, as expected, the RPC mainly by increasing the level of cholines to improve energy metabolism. In future studies, the combined effect of GLY and RPC on ewes suffering malnutrition should be investigated and also its underling mechanisms.

Conclusion

Urine metabolome analysis revealed that malnutrition clearly induced mobilisation of lipids and amino acids by hormones, leading to the disorder of lipid metabolism, amino acid metabolism and the TCA cycle. Both GLY and RPC counteracted some of these changes and modulated the urine metabolome in advanced pregnant ewes suffering from malnutrition. This study can be considered a reliable reference for human nutrition studies, and GLY and choline may have a positive role in pregnant human health.

Acknowledgements

The authors wish to thank Hossam-eldin Seddik for language and structure suggestions. The authors also thank Shanghai Sensichip Infotech Co. Ltd, Shanghai, People's Republic of China.

This research was funded by the National Key Research and Development Program of China (grant number 2016YFD0501200), Jiangsu Agriculture Science and Technology Innovation Fund (grant number CX(18)2003) and Science and Technology Project of Huzhou City of China (grant number 2017GY18).

The authors' contributions are as follows: C. G. and S. M. designed research; Y. X., Y. Y., H. X. and F. H. conducted research. C. G. and S. M. analysed data and wrote the paper. S. M. had primary responsibility for final content.

The authors declare that there are no conflicts of interest.

Supplementary material

For supplementary materials referred to in this article, please visit https://doi.org/10.1017/S000711452000063X

References

- Cal-Pereyra L, Acosta-Dibarrat J, Benech A, et al. (2012) Ewe pregnancy toxemia. Review. Rev Mex Cienc Pecu 3, 247–264.
- Rook JS & Herdt TH (2000) Pregnancy toxemia of ewes, does, and beef cows. Vet Clin North Am Food Anim Pract 16, 293–317.

- Yue GH (1996) Reproductive characteristics of Chinese Hu sheep. Anim Reprod Sci 44, 223–230.
- Herdt TH (2000) Ruminant adaptation to negative energy balance. Influences on the etiology of ketosis and fatty liver. Vet Clin North Am Food Anim Pract 16, 215–230.
- Esposito G, Irons PC, Webb EC, et al. (2014) Interactions between negative energy balance, metabolic diseases, uterine health and immune response in transition dairy cows. Anim Reprod Sci 144, 60–71.
- Chilliard Y, Ferlay A, Faulconnier Y, et al. (2000) Adipose tissue metabolism and its role in adaptations to undernutrition in ruminants. Proc Nutr Soc 59, 127–134.
- 7. Herdt TH & Emery RS (1992) Therapy of diseases of ruminant intermediary metabolism. *Vet Clin North Am Food Anim Pract* **8**, 91–106.
- Osman MA, Allen PS, Mehyar NA, et al. (2008) Acute metabolic responses of postpartal dairy cows to subcutaneous glucagon injections, oral glycerol, or both. J Dairy Sci 91, 3311–3322.
- Hunt E (1976) Treatment of pregnancy toxaemia in ewes by induction of parturition. Aust Vet J 52, 338–339.
- Omazic AW, Kronqvist C, Zhongyan L, et al. (2015) The fate of glycerol entering the rumen of dairy cows and sheep. J Anim Physiol Anim Nutr 99, 258–264.
- Piantoni R & Allen MS (2015) Evaluation of propylene glycol and glycerol infusions as treatments for ketosis in dairy cows. *I Dairy Sci* 98, 5429–5439.
- Shahsavari A, D'Occhio MJ & Al Jassim R (2016) The role of rumen-protected choline in hepatic function and performance of transition dairy cows. *Br J Nutr* 116, 35–44.
- 13. Ametaj BN, Zebeli Q, Saleem F, *et al.* (2010) Metabolomics reveals unhealthy alterations in rumen metabolism with increased proportion of cereal grain in the diet of dairy cows. *Metabolomics* **6**, 583–594.
- Zhao S, Zhao J, Bu D, et al. (2014) Metabolomics analysis reveals large effect of roughage types on rumen microbial metabolic profile in dairy cows. Lett Appl Microbiol 59, 79–85.
- Yang YX, Zheng N, Zhao XW, et al. (2016) Metabolomic biomarkers identify differences in milk produced by Holstein cows and other minor dairy animals. J Proteomics 136, 174–182.
- Barry JS & Anthony RV (2008) The pregnant sheep as a model for human pregnancy. *Theriogenology* 69, 55–67.
- Gonzalez-Bulnes A, Astiz S, Parraguez VH, et al. (2016) Empowering translational research in fetal growth restriction: sheep and swine animal models. Curr Pharm Biotechnol 17, 848–855.
- Xue YF, Guo CZ, Hu F, et al. (2019) Molecular mechanisms of lipid metabolism disorder in livers of ewes with pregnancy toxemia. Animal 13, 992–999.
- de Veth MJ, Artegoitia VM, Campagna SR, et al. (2016) Choline absorption and evaluation of bioavailability markers when supplementing choline to lactating dairy cows. J Dairy Sci 99, 9732–9744.
- Baldi A & Pinotti L (2006) Choline metabolism in high-producing dairy cows: metabolic and nutritional basis. *Can J Anim Sci* 86, 207–212.
- Garcia-Garcia RM (2012) Integrative control of energy balance and reproduction in females. ISRN Vet Sci 2012, 121389.
- McCue MD (2010) Starvation physiology: reviewing the different strategies animals use to survive a common challenge. Comp Biochem Physiol A Mol Integr Physiol 156, 1–18.
- Drackley JK, Overton TR & Douglas GN (2001) Adaptations of glucose and long-chain fatty acid metabolism in liver of dairy cows during the periparturient period. *J Dairy Sci* 84, E100–E112.
- Fowden AL, Mijovic J & Silver M (1993) The effects of cortisol on hepatic and renal gluconeogenic enzyme-activities in the sheep fetus during late-gestation. *J Endocrinol* 137, 213–222.



 Wei X, Yin Q, Zhao H, et al. (2018) Metabolomics for the effect of biotin and nicotinamide on transition dairy cows. J Agric Food Chem 66, 5723–5732.

- Chandler TL & White HM (2017) Choline and methionine differentially alter methyl carbon metabolism in bovine neonatal hepatocytes. PLOS ONE 12, e0171080.
- Li Z, Agellon LB, Allen TM, et al. (2006) The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 3, 321–331.
- Rivadeneira DE, Grobmyer SR, Naama HA, et al. (2001) Malnutrition-induced macrophage apoptosis. Surgery 129, 617–625.
- Ruderman NB (1975) Muscle amino acid metabolism and gluconeogenesis. Annu Rev Med 26, 245–258.
- Mithieux G, Rajas F, Gautier-Stein A, et al. (2017) Adaptation of hepatic, renal and intestinal gluconeogenesis during food deprivation. In Handbook of Famine, Starvation, and Nutrient Deprivation, pp. 1–15 [V Preedy and V Patel, editors]. Cham: Springer.

- 31. Ferraro SM, Mendoza GD, Miranda LA, et al. (2016) In vitro ruminal fermentation of glycerol, propylene glycol and molasses combined with forages and their effect on glucose and insulin blood plasma concentrations after an oral drench in sheep. Anim Feed Sci Technol 213, 74–80.
- 32. Mitrakou A (2011) Kidney: its impact on glucose homeostasis and hormonal regulation. *Diabetes Res Clin Pract* **93**, S66–S72.
- 33. Zeisel SH (2000) Choline: an essential nutrient for humans. *Nutrition* **16**, 669–671.
- 34. Zom RLG, van Baal J, Goselink RMA, *et al.* (2011) Effect of rumen-protected choline on performance, blood metabolites, and hepatic triacylglycerols of periparturient dairy cattle. *J Dairy Sci* **94**, 4016–4027.
- 35. Cooke RF, del Rio NS, Caraviello DZ, et al. (2007) Supplemental choline for prevention and alleviation of fatty liver in dairy cattle. *J Dairy Sci* **90**, 2413–2418.
- Sheard NF & Krasin B (1994) Restricting food intake does not exacerbate the effects of a choline-deficient diet on tissue carnitine concentrations in rats. J Nutr 124, 738.

